Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs

Abstract

Mitochondrial diseases are maternally inherited heterogeneous disorders that are primarily caused by mitochondrial DNA (mtDNA) mutations. Depending on the ratio of mutant to wild-type mtDNA, known as heteroplasmy, mitochondrial defects can result in a wide spectrum of clinical manifestations. Mitochondria-targeted endonucleases provide an alternative avenue for treating mitochondrial disorders via targeted destruction of the mutant mtDNA and induction of heteroplasmic shifting. Here, we generated mitochondrial disease patient-specific induced pluripotent stem cells (MiPSCs) that harbored a high proportion of m.3243A>G mtDNA mutations and caused mitochondrial encephalomyopathy and stroke-like episodes (MELAS). We engineered mitochondrial-targeted transcription activator-like effector nucleases (mitoTALENs) and successfully eliminated the m.3243A>G mutation in MiPSCs. Off-target mutagenesis was not detected in the targeted MiPSC clones. Utilizing a dual fluorescence iPSC reporter cell line expressing a 3243G mutant mtDNA sequence in the nuclear genome, mitoTALENs displayed a significantly limited ability to target the nuclear genome compared with nuclear-localized TALENs. Moreover, genetically rescued MiPSCs displayed normal mitochondrial respiration and energy production. Moreover, neuronal progenitor cells differentiated from the rescued MiPSCs also demonstrated normal metabolic profiles. Furthermore, we successfully achieved reduction in the human m.3243A>G mtDNA mutation in porcine oocytes via injection of mitoTALEN mRNA. Our study shows the great potential for using mitoTALENs for specific targeting of mutant mtDNA both in iPSCs and mammalian oocytes, which not only provides a new avenue for studying mitochondrial biology and disease but also suggests a potential therapeutic approach for the treatment of mitochondrial disease, as well as the prevention of germline transmission of mutant mtDNA.

Keywords

mitochondria / iPSCs / TALEN / MELAS

References

[1] Alexeyev MF, Venediktova N, Pastukh V, Shokolenko I, Bonilla G, Wilson GL (2008) Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MILS syndromes. Gene Ther 15(7):516–523

[2] Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F (1981) Sequence and organization of the human mitochondrial genome. Nature 290(5806):457–465

[3] Bacman SR, Williams SL, Garcia S, Moraes CT (2010) Organspecific shifts in mtDNA heteroplasmy following systemic delivery of a mitochondria-targeted restriction endonuclease. Gene Ther 17(6):713–720

[4] Bacman SR, Williams SL, Pinto M, Peralta S, Moraes CT (2013) Specific elimination of mutant mitochondrial genomes in patientderived cells by mitoTALENs. Nat Med 19(9):1111–1113

[5] Boch J, Bonas U (2010) Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annu Rev Phytopathol 48:419–436

[6] Brown DT, Herbert M, Lamb VK, Chinnery PF, Taylor RW, Lightowlers RN, Craven L, Cree L, Gardner JL, Turnbull DM (2006) Transmission of mitochondrial DNA disorders: possibilities for the future. Lancet 368(9529):87–89

[7] Chan DC (2006) Mitochondria: dynamic organelles in disease, aging, and development. Cell 125(7):1241–1252

[8] Farrar GJ, Chadderton N, Kenna PF, Millington-Ward S (2013) Mitochondrial disorders: aetiologies, models systems, and candidate therapies. Trends Genet 29(8):488–497

[9] Folmes CD, Martinez-Fernandez A, Perales-Clemente E, Li X, McDonald A, Oglesbee D, Hrstka SC, Perez-Terzic C, Terzic A, Nelson TJ (2013) Disease-causing mitochondrial heteroplasmy segregated within induced pluripotent stem cell clones derived from a patient with MELAS. Stem Cells 31(7):1298–1308

[10] Goto Y, Nonaka I, Horai S (1990) A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348(6302):651–653

[11] Griffin J, Emery BR, Huang I, Peterson CM, Carrell DT (2006) Comparative analysis of follicle morphology and oocyte diameter in four mammalian species (mouse, hamster, pig, and human). J Exp Clin Assist Reprod 3:2

[12] Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, Cohen BH (2007) Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 120(6):1326–1333

[13] Hamalainen RH, Manninen T, Koivumaki H, Kislin M, Otonkoski T, Suomalainen A (2013) Tissue- and cell-type-specific manifestations of heteroplasmic mtDNA 3243A>G mutation in human induced pluripotent stem cell-derived disease model. Proc Natl Acad Sci USA 110(38):E3622–E3630

[14] Hatakeyama H, Goto Y (2016) Concise review: heteroplasmic mitochondrial DNA mutations and mitochondrial diseases: toward iPSC-Based disease modeling, drug discovery, and regenerative therapeutics. Stem Cells 34(4):801–808

[15] Ingman M, Kaessmann H, Paabo S, Gyllensten U (2000) Mitochondrial genome variation and the origin of modern humans. Nature 408(6813):708–713

[16] Jo A, Ham S, Lee GH, Lee YI, Kim S, Lee YS, Shin JH, Lee Y (2015) Efficient Mitochondrial Genome Editing by CRISPR/Cas9. Biomed Res Int 2015:305716

[17] Kodaira M, Hatakeyama H, Yuasa S, Seki T, Egashira T, Tohyama S, Kuroda Y, Tanaka A, Okata S, Hashimoto H (2015) Impaired respiratory function in MELAS-induced pluripotent stem cells with high heteroplasmy levels. FEBS Open Bio 5:219–225

[18] Li M, Zhong Z, Zhu J, Xiang D, Dai N, Cao X, Qing Y, Yang Z, Xie J, Li Z (2010) Identification and characterization of mitochondrial targeting sequence of human apurinic/apyrimidinic endonuclease 1. J Biol Chem 285(20):14871–14881

[19] Lionaki E, Gkikas I, Tavernarakis N (2016) Differential protein distribution between the nucleus and mitochondria: implications in aging. Front Genet 7:162

[20] Ma H, Folmes CD, Wu J, Morey R, Mora-Castilla S, Ocampo A, Ma L, Poulton J, Wang X, Ahmed R (2015) Metabolic rescue in pluripotent cells from patients with mtDNA disease. Nature 524 (7564):234–238

[21] Minczuk M, Papworth MA, Kolasinska P, Murphy MP, Klug A (2006) Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase. Proc Natl Acad Sci USA 103 (52):19689–19694

[22] Moretton A, Morel F, Macao B, Lachaume P, Ishak L, Lefebvre M, Garreau-Balandier I, Vernet P, Falkenberg M, Farge G (2017) Selective mitochondrial DNA degradation following double-strand breaks. PLoS ONE 12(4):e0176795

[23] Reddy P, Ocampo A, Suzuki K, Luo J, Bacman SR, Williams SL, Sugawara A, Okamura D, Tsunekawa Y, Wu J (2015) Selective elimination of mitochondrial mutations in the germline by genome editing. Cell 161(3):459–469

[24] Rooney JP, Ryde IT, Sanders LH, Howlett EH, Colton MD, Germ KE, Mayer GD, Greenamyre JT, Meyer JN (2015) PCR based determination of mitochondrial DNA copy number in multiple species. Methods Mol Biol 1241:23–38

[25] Russell O, Turnbull D (2014) Mitochondrial DNA disease-molecular insights and potential routes to a cure. Exp Cell Res 325(1):38–43

[26] Smith AJ, Bainbridge JW, Ali RR (2012) Gene supplementation therapy for recessive forms of inherited retinal dystrophies. Gene Ther 19(2):154–161

[27] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872

[28] Taylor RW, Turnbull DM (2005) Mitochondrial DNA mutations in human disease. Nat Rev Genet 6(5):389–402

[29] Vogel G (2014) Assisted reproduction. FDA considers trials of ‘threeparent embryos’. Science 343(6173):827–828

[30] Wallace DC (2013) A mitochondrial bioenergetic etiology of disease. J Clin Invest 123(4):1405–1412

[31] Wang T, Sha H, Ji D, Zhang HL, Chen D, Cao Y, Zhu J (2014) Polar body genome transfer for preventing the transmission of inherited mitochondrial diseases. Cell 157(7):1591–1604

[32] Wu K, Chen T, Huang S, Zhong C, Yan J, Zhang X, Li J, Gao Y, Zhao H, Chen ZJ (2017) Mitochondrial replacement by pre-pronuclear transfer in human embryos. Cell Res 27(6):834–837

[33] Yamada M, Emmanuele V, Sanchez-Quintero MJ, Sun B, Lallos G, Paull D, Zimmer M, Pagett S, Prosser RW, Sauer MV (2016) Genetic drift can compromise mitochondrial replacement by nuclear transfer in human oocytes. Cell Stem Cell 18(6):749–754

[34] Zhang J, Guo J, Fang W, Jun Q, Shi K (2015) Clinical features of MELAS and its relation with A3243G gene point mutation. Int J Clin Exp Pathol 8(10):13411–13415

RIGHTS & PERMISSIONS

2018 The Author(s) 2018. This article is an open access publication